Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,153,091 shares of the life sciences company's stock after selling 14,966 shares during the quarter. Janus Henderson Group PLC owned about 1.36% of Illumina worth $287,718,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter valued at about $32,000. Assetmark Inc. boosted its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina in the 4th quarter valued at approximately $45,000. Lee Danner & Bass Inc. acquired a new stake in Illumina during the 4th quarter worth approximately $48,000. Finally, V Square Quantitative Management LLC boosted its position in Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock worth $52,000 after buying an additional 132 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Activity at Illumina

In related news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.17% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research analyst reports. Canaccord Genuity Group lowered their price objective on shares of Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Citigroup cut their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley cut their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.70.

Illumina Trading Up 3.4%

ILMN stock traded up $2.72 during midday trading on Friday, hitting $83.62. 2,338,618 shares of the company's stock were exchanged, compared to its average volume of 2,316,765. The business has a 50-day simple moving average of $78.48 and a two-hundred day simple moving average of $111.12. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $13.23 billion, a PE ratio of -10.89, a P/E/G ratio of 1.60 and a beta of 1.35. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same period in the previous year, the firm posted $0.98 earnings per share. The company's revenue was down 1.4% on a year-over-year basis. On average, sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.